Dermata Therapeutics, Inc.
DRMADrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
DMT310
Acne Vulgaris
DMT210 Topical Gel 5%
Acne Rosacea
DMT210 Topical Gel
Atopic Dermatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DMT310 | Phase 3 | Acne Vulgaris | - | - |
DMT210 Topical Gel 5% | Phase 2 | Acne Rosacea | - | - |
DMT210 Topical Gel | Phase 2 | Atopic Dermatitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Dermata Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Dermata Therapeutics, Inc.'s (DRMA) pipeline across Phase 3, Phase 2. Its lead program is DMT310 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dermata Therapeutics, Inc.'s next FDA catalyst?→
Dermata Therapeutics, Inc.'s (DRMA) next tracked catalyst is a Earnings expected November 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DRMA biotech catalysts?→
Add DRMA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dermata Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.